Domestic Innovation in Non-Invasive Glaucoma Diagnosis and Treatment Gains Momentum with Successful Angel Funding
【Perspective · Ophthalmology Industry Navigation】
Major Events Monthly Report | Editor's Recommended Article
Winning Atlas· Centralized Procurement Scaling Up | Ophthalmic Optometry Column
Recently,Hangzhou Little Eagle Sharp Vision Technology Co., Ltd.("Little Eagle Vision" for short)Announcement of Successful CompletionAngel Round Financing, this round of financing was jointly participated by well-known investment institutions, industry capital, and individual investors. This financing will provide the company withClinical advancement, registration submission, and market expansion of the two core productsProviding strong support to further advance the commercialization of non-invasive glaucoma diagnosis and treatment technologies.
Glaucoma, as one of the leading causes of blindness globally, highlights the increasing importance of early diagnosis and treatment. Xiaoying Ruishi, with its expertise in “Intraocular Pressure Monitoring + Treatment Integration"The innovative layout in this field is gradually breaking the traditional ophthalmology treatment model, bringing patients more convenient and safer diagnosis and treatment options."
It is reported that Little Eagle VisionAlreadySecured tens of millions of yuan in tentative orders, and continue to ship through multiple channels.As the product gradually expands in the market and the customer base continues to grow, the company will further deepen its technology research and development in the future, promoting the globalization of non-invasive glaucoma diagnosis and treatment technologies.
# Innovative Technology Breaks Through the Bottleneck of Glaucoma Treatment
The technological innovation of Little Eagle Rui Shi is embodied in its two core products:
"Hawk Eye I" Handheld Tonometer
Early diagnosis of glaucoma is crucial, while traditional methods of intraocular pressure measurement often rely on cumbersome operations and require high patient cooperation. To overcome these challenges, "HawkEye Generation One" adoptsAutomatic AlignmentAndAnti-shake Fixation...and other innovative technologies have made IOP measurement more convenient and precise. Patients can easily perform self-testing at home, reducing the threshold for seeking medical care, and can...Achieve More Efficient Early Glaucoma Screening。
Focused Ultrasound Glaucoma Ablation Device
This device treats glaucoma by utilizing focused ultrasound technology.Avoids the invasive procedures of traditional surgery., significantly reducing the risks and recovery time for patients. As an innovative upgraded product made in China, the focused ultrasound glaucoma ablation deviceAnimal experiments have been completed., and preliminarily verified its role in treatmentSafetyAndEffectiveness, and is expected to become an important tool for glaucoma treatment in the future.
# Strong Support Behind the Source of Innovation
The breakthrough achieved by Little Eagle Rui Vision in the field of non-invasive glaucoma diagnosis and treatment technology is inseparable from itsA strong team and deep R&D accumulation behind。
The core team of the company consists of research talents from top universities in China, such as Peking University, Tsinghua University, and Zhejiang University. The team members have rich academic and practical experience in the fields of ophthalmology, medical engineering, and medical industrialization.
In terms of technology development, Xiaoying Ruishi throughDeep Integration of Industry, Academia, Research, and Medicine, ensuring the rapid transformation and practical application of innovative technologies.
The company has established close cooperative relationships with multiple clinical institutions, committing to seamlessly connect theoretical research with clinical needs. In these collaborations, clinical experts and researchers communicate closely, promoting continuous optimization of products in terms of safety, efficacy, and more, enabling each product to have a solid foundation in science and practice.
In addition, the team also focuses onInternational Perspective, combining the development trends of the global ophthalmology industry, actively explore the frontier technologies in glaucoma diagnosis and treatment and the needs of emerging markets.
This strong team background not only provides the company with a steady stream of innovative momentum but also gives Little Eagle Vision a competitive edge in the future of glaucoma treatment.
# Innovative Products Spark Industry Attention
Ultrasound Ciliary Plasty (UCP), as an innovative technology for glaucoma treatment, is rapidly leading industry changes. ThroughHigh-intensity focused ultrasound energy acts on the ciliary body, thereby reducing aqueous humor production and enhancing its outflow.; It not only addresses the limitations of traditional treatment methods but also offers a new treatment option for patients with refractory glaucoma.
UCP TechnologySince gaining approval from the Chinese National Medical Products Administration in 2017, it has been widely used both in China and internationally, especially inRefractory GlaucomaAnd has shown significant effects in the treatment of other complex types of glaucoma, withNo surgical incision required、Short-term RecoveryAndFew complicationsThe advantages have gradually become the preferred treatment option for many ophthalmologists.
In China,There have been more than50 Medical InstitutionsIntroduced UCP Technology, including some of the top tertiary hospitals and eye specialty hospitals. Particularly in the East China, South China, and North China regions,Eye Hospital of Wenzhou Medical University、Shantou University · The Chinese University of Hong Kong Joint Shantou International Eye CenterAuthoritative institutions have carried out a large number of UCP surgeries, andThe annual number of surgeries continues to show an increasing trend.。
The successful experience of these hospitals has laid the foundation for the further promotion of UCP technology, and also demonstrated the wide adaptability and good therapeutic effects of this technology in the market.
The Rapid Growth of Market Demandhas also prompted a gradual increase in equipment procurement. In recent years,EYE TECH CAREUCP Device（Ultrasonic Glaucoma Treatment DeviceHas already taken a dominant position in the Chinese market, andNo domestically produced devices of the same type have been approved for marketing in China.。
In terms of the pricing system,The cost of UCP surgery is higher compared to traditional glaucoma surgery., but due to its advantages of being non-invasive and having a quick recovery, the recognition of its value by patients and medical institutions continues to increase. The specific pricing system is as follows:
Surgical Operation Fee: According to the filing of the provincial medical service price catalog, the operating costs for UCP surgery are generally inRMB 3500 to RMB 6000Between. For example, the registered price in Zhejiang Province is¥5800(Including intraoperative ultrasound guidance), the registered price in Sichuan Province is¥4200(Not including intraoperative monitoring).
Specialized Consumables Fee: UCP surgery requires the use of disposable ultrasound probes, with imported brands priced atRMB 8,000 to RMB 12,000/UnitThis portion of the cost accounts for a significant proportion of the total surgical expenses, especially in the case of high-end equipment and imported brands, where price differences are more pronounced.
Auxiliary Examination Fee: Preoperative auxiliary examination fees, such as UBM examination, visual field assessment, etc., are priced at¥800 to ¥1500Between.
In terms of medical insurance coverage,Although UCP surgery has not yet been fully covered by medical insurance across China, pilot programs have begun in some regions.. For example,Zhejiang ProvinceIt is expected to include UCP in the special treatment projects of serious illness insurance, with a reimbursement ratio of50%; andGuangdong ProvinceIn some regions, the DRG payment model has been adopted, and the payment standard for refractory glaucoma cases is￥19,800. Some ophthalmology groups in private institutions have introduced installment payment plans to help alleviate the financial burden on patients.
WithThe continuous maturation of technologyAndLocalization of EquipmentThe process is accelerating, and UCP is expected to become an important component in the field of glaucoma treatment, with rapid growth anticipated in the coming years. According to industry forecasts,2025The number of UCP surgeries will break through10,000 cases, and with theReform of Payment MethodsThe popularity of UCP will further increase in the future.
Little Eagle Vision is expected to integrate this cutting-edge technology with its existing core products, which will...Glaucoma Diagnosis and Treatment MarketTo occupy a more important position in China.
# Company Profile
Hangzhou Little Eagle Vision Technology Co., Ltd. was established in February 2025. The company was founded by a team primarily composed of members from Tsinghua University and Peking University, focusing on the development and industrialization of diagnostic and therapeutic technologies for pan-ophthalmic diseases. Targeting markets with high willingness to pay, such as glaucoma and dry eye syndrome, the company provides innovative medical solutions. Its product line covers markets ranging from consumer-grade to Class II and Class III, with some products already commercially available.
GOC2025
Ophthalmology Solutions Case
Research on Ophthalmic Instruments Industry
